Real world effectiveness and satisfaction with secukinumab in the treatment of patients with psoriatic arthritis: a population survey in five European countries

References

• Gladman DD. Early psoriatic arthritis. Rheum Dis Clin North Am. 2012;38(2):373–386.
   PubMed Web of Science ®Google Scholar
• Lee S, Mendelsohn A, Sarnes E. The burden of psoriatic arthritis: a literature review from a global health systems perspective. P T. 2010;35(12):680–689.
   PubMedGoogle Scholar
• Ogdie A, Weiss P. The epidemiology of psoriatic arthritis. Rheum Dis Clin North Am. 2015;41(4):545–568.
   PubMed Web of Science ®Google Scholar
• Husni ME. Comorbidities in psoriatic arthritis. Rheum Dis Clin North Am. 2015;41(4):677–698.
   PubMed Web of Science ®Google Scholar
• Antoni C, Krueger GG, de Vlam K, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis. 2005;64(8):1150–1157.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Gladman DD, Ritchlin CT, Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005;52(10):3279–3289.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004;50(7):2264–2272.
   PubMed Web of Science ®Google Scholar
• Gossec L, Smolen JS, Gaujoux-Viala C, European League Against Rheumatism, et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis. 2012;71(1):4–12.
   PubMed Web of Science ®Google Scholar
• Gossec L, Smolen JS, Ramiro S, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis. 2016;75(3):499–510.
   PubMed Web of Science ®Google Scholar
• Coates LC, Kavanaugh A, Mease PJ, et al. Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol. 2016;68(5):1060–1071.
   PubMed Web of Science ®Google Scholar
• Merola JF, Lockshin B, Mody EA. Switching biologics in the treatment of psoriatic arthritis. Semin Arthritis Rheum. 2017;47(1):29–37.
   PubMed Web of Science ®Google Scholar
• Ritchlin C, Rahman P, Kavanaugh A, on behalf of the PSUMMIT 2 Study Group, et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis. 2014;73(6):990–999.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013;382(9894):780–789.
   PubMed Web of Science ®Google Scholar
• Mease PJ, McInnes IB, Kirkham B, et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med. 2015;373(14):1329–1339.
   PubMed Web of Science ®Google Scholar
• Nash P, Kirkham B, Okada M, et al. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. Lancet. 2017;389(10086):2317–2327.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Gottlieb AB, van der Heijde D, et al. Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis. Ann Rheum Dis. 2017;76(9):1550–1558.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014;73(6):1020–1026.
   PubMed Web of Science ®Google Scholar
• Gladman D, Rigby W, Azevedo VF, et al. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med. 2017;377(16):1525–1536.
   PubMed Web of Science ®Google Scholar
• Cantatore FP, Maruotti N, Corrado A, et al. Anti-angiogenic effects of biotechnological therapies in rheumatic diseases. Biologics. 2017;11:123–128.
   PubMed Web of Science ®Google Scholar
• Kagami S, Rizzo HL, Lee JJ, et al. Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol. 2010;130(5):1373–1383.
   PubMed Web of Science ®Google Scholar
• Murdaca G, Colombo BM, Puppo F. The role of Th17 lymphocytes in the autoimmune and chronic inflammatory diseases. Intern Emerg Med. 2011;6(6):487–495.
   PubMed Web of Science ®Google Scholar
• Menon B, Gullick NJ, Walter GJ, et al. Interleukin-17 + CD8+ T cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progression. Arthritis Rheumatol. 2014;66(5):1272–1281.
   PubMed Web of Science ®Google Scholar
• Baeten D, Baraliakos X, Braun J, et al. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet. 2013;382(9906):1705–1713.
   PubMed Web of Science ®Google Scholar
• Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis–results of two phase 3 trials. N Engl J Med. 2014;371(4):326–338.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Kavanaugh A, Reimold A, et al. Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial. RMD Open. 2018;4(2):e000723.
   PubMed Web of Science ®Google Scholar
• Michelsen B, Heegaard Brahe C, Jacobsson LTH, et al. Remission and drug retention rates of secukinumab in 1549 patients with psoriatic arthritis treated in routine care – pooled data from the observational EUROSPA research collaboration network. Ann Rheum Dis. 2019;78:1281–1282.
   Web of Science ®Google Scholar
• Anderson P, Benford M, Harris N, et al. Real-world physician and patient behaviour across countries: disease-specific programmes – a means to understand. Curr Med Res Opin. 2008;24(11):3063–3072.
   PubMed Web of Science ®Google Scholar
• van der Heijde DM, van 't Hof MA, van Riel PL, et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis. 1990;49(11):916–920.
   PubMed Web of Science ®Google Scholar
• Fredriksson T, Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica. 1978;157(4):238–244.
   PubMedGoogle Scholar
• Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum. 1993;36(6):729–740.
   PubMed Web of Science ®Google Scholar
• Public Policy Committee ISoP. Guidelines for good pharmacoepidemiology practice (GPP). Pharmacoepidemiol Drug Saf. 2016;25(1):2–10.
   PubMed Web of Science ®Google Scholar
• Vandenbroucke JP, von Elm E, Altman DG, STROBE initiative, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Ann Intern Med. 2007;147(8):W163–W94.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386(9999):1137–1146.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Mease PJ, Ritchlin CT, et al. Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study. Rheumatology. 2017;56(11):1993–2003.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Kavanaugh A, Reimold A, FUTURE 1 study group, et al. Secukinumab provides sustained improvements in the signs and symptoms of psoriatic arthritis: final 5-year results from the phase 3 FUTURE 1 study. ACR Open Rheumatol. 2020;2(1):18–25.
   PubMedGoogle Scholar
• Michelsen B, Georgiadis S, DI Giuseppe D, et al. SAT0430 Secukinumab effectiveness in 1543 patients with psoriatic arthritis treated in routine clinical practice in 13 European countries in the EuroSpA Research Collaboration network. Ann Rheum Dis. 2020;79(Suppl 1):1169.2–1171.
   Web of Science ®Google Scholar
• Walsh JA, Adejoro O, Chastek B, et al. Treatment patterns among patients with psoriatic arthritis treated with a biologic in the United States: descriptive analyses from an administrative claims database. J Manag Care Spec Pharm. 2018;24(7):623–631.
   PubMed Web of Science ®Google Scholar
• Soriano ER, Zazzetti F, Alves Pereira I, et al. Physician-patient alignment in satisfaction with psoriatic arthritis treatment in Latin America. Clin Rheumatol. 2020;39(6):1859–1869.
   PubMed Web of Science ®Google Scholar
• Furst DE, Tran M, Sullivan E, et al. Misalignment between physicians and patient satisfaction with psoriatic arthritis disease control. Clin Rheumatol. 2017;36(9):2045–2054.
   PubMed Web of Science ®Google Scholar